{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:47:59Z","timestamp":1782604079616,"version":"3.54.5"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/wco.0000000000000093","type":"journal-article","created":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T15:27:21Z","timestamp":1398180441000},"page":"279-289","source":"Crossref","is-referenced-by-count":64,"title":["Longitudinally extensive transverse myelitis"],"prefix":"10.1097","volume":"27","author":[{"given":"W. Oliver","family":"Tobin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Weinshenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia F.","family":"Lucchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210206","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1212\/WNL.59.4.499","article-title":"","volume":"59","year":"2002","journal-title":"Neurology"},{"key":"R2-6-20210206","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1148\/radiology.195.3.7754002","article-title":"Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters.","volume":"195","author":"Tartaglino","year":"1995","journal-title":"Radiology"},{"key":"R3-6-20210206","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","article-title":"Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.","volume":"59","author":"Weinshenker","year":"2006","journal-title":"Ann Neurol"},{"key":"R4-6-20210206","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00415-009-5058-x","article-title":"Long-term outcome of acute and subacute myelopathies.","volume":"256","author":"Debette","year":"2009","journal-title":"J Neurol"},{"issue":"Pt 7","key":"R5-6-20210206","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devics neuromyelitis optica.","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"R6-6-20210206","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"R8-6-20210206","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-2094-10-8","article-title":"The history of neuromyelitis optica.","volume":"10","author":"Jarius","year":"2013","journal-title":"J Neuroinflammation"},{"key":"R9-6-20210206","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00415-008-0545-z","article-title":"Preferential spinal central gray matter involvement in neuromyelitis optica: an MRI study.","volume":"255","author":"Nakamura","year":"2008","journal-title":"J Neurol"},{"key":"R10-6-20210206","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica.","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology"},{"key":"R11-6-20210206","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica.","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"R12-6-20210206","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica.","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"R13-6-20210206","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1177\/1352458512472753","article-title":"Hypogeusia as a symptom of neuromyelitis optica spectrum disorder.","volume":"19","author":"Iones","year":"2013","journal-title":"Mult Scler"},{"key":"R14-6-20210206","doi-asserted-by":"crossref","first-page":"e1039","DOI":"10.1542\/peds.2007-2758","article-title":"Spectrum of pediatric neuromyelitis optica.","volume":"122","author":"Lotze","year":"2008","journal-title":"Pediatrics"},{"key":"R15-6-20210206","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/01.wnl.0000343001.36493.ae","article-title":"Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders.","volume":"72","author":"Magana","year":"2009","journal-title":"Neurology"},{"key":"R16-6-20210206","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jamaneurol.2013.5055","article-title":"Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis.","volume":"71","author":"Jiao","year":"2014","journal-title":"JAMA Neurol"},{"key":"R18-6-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica.","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"key":"R19-6-20210206","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.neuroscience.2004.07.055","article-title":"The role of aquaporin-4 in blood-brain barrier development and integrity: studies in animal and cell culture models.","volume":"129","author":"Nicchia","year":"2004","journal-title":"Neuroscience"},{"issue":"Pt 5","key":"R20-6-20210206","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"issue":"Pt 5","key":"R21-6-20210206","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"key":"R22-6-20210206","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/1352458513505350","article-title":"Aquaporin-4 antibody-positive myelitis initially biopsied for suspected spinal cord tumors: diagnostic considerations.","volume":"20","author":"Sato","year":"2014","journal-title":"Mult Scler"},{"key":"R23-6-20210206","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol"},{"key":"R24-6-20210206","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes.","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R25-6-20210206","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamaneurol.2013.3124","article-title":"Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica.","volume":"70","author":"Matiello","year":"2013","journal-title":"JAMA Neurol"},{"key":"R26-6-20210206","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Antiaquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"key":"R27-6-20210206","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1373\/clinchem.2008.116848","article-title":"AQP4-IgG immunoprecipitation assay optimization.","volume":"55","author":"Apiwattanakul","year":"2009","journal-title":"Clin Chem"},{"key":"R28-6-20210206","first-page":"573","article-title":"Mildly abnormal retinal function in transgenic mice without Muller cell aquaporin-4 water channels.","volume":"43","author":"Li","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R29-6-20210206","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1096\/fj.07-104836","article-title":"Impaired olfaction in mice lacking aquaporin-4 water channels.","volume":"22","author":"Lu","year":"2008","journal-title":"FASEB J"},{"key":"R30-6-20210206","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11940-008-0007-z","article-title":"Neuromyelitis optica.","volume":"10","author":"Wingerchuk","year":"2008","journal-title":"Curr Treat Options Neurol"},{"key":"R31-6-20210206","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"key":"R32-6-20210206","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3988\/jcn.2013.9.1.36","article-title":"Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating antiaquaporin-4 antibody levels.","volume":"9","author":"Kim","year":"2013","journal-title":"J Clin Neurol"},{"key":"R33-6-20210206","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1352458506071174","article-title":"Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica.","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"issue":"Suppl 1","key":"R34-6-20210206","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10875-012-9796-7","article-title":"Neuromyelitis optica: potential roles for intravenous immunoglobulin.","volume":"33","author":"Wingerchuk","year":"2013","journal-title":"J Clin Immunol"},{"key":"R35-6-20210206","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","article-title":"Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients.","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler"},{"key":"R36-6-20210206","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nrl.2012.03.014","article-title":"The effect of intravenous immunoglobulin on neuromyelitis optica.","volume":"28","author":"Magraner","year":"2013","journal-title":"Neurologia"},{"key":"R37-6-20210206","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devics neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine.","volume":"51","author":"Mandler","year":"1998","journal-title":"Neurology"},{"key":"R38-6-20210206","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"R39-6-20210206","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol"},{"key":"R40-6-20210206","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica.","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"R41-6-20210206","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"key":"R42-6-20210206","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"R43-6-20210206","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","article-title":"Transient increases in antiaquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels.","volume":"18","author":"Nakashima","year":"2011","journal-title":"J Clin Neurosci"},{"key":"R44-6-20210206","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"R46-6-20210206","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","article-title":"Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab.","volume":"23","author":"Araki","year":"2013","journal-title":"Mod Rheumatol"},{"key":"R47-6-20210206","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy.","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"key":"R48-6-20210206","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bpa.12085","article-title":"Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO.","volume":"23","author":"Verkman","year":"2013","journal-title":"Brain Pathol"},{"key":"R49-6-20210206","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ana.23741","article-title":"Enzymatic deglycosylation converts pathogenic neuromyelitis optica antiaquaporin-4 immunoglobulin G into therapeutic antibody.","volume":"73","author":"Tradtrantip","year":"2013","journal-title":"Ann Neurol"},{"key":"R50-6-20210206","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.semarthrit.2010.05.005","article-title":"Neuromyelitis optica spectrum disorder as an initial presentation of primary Sjogrens syndrome.","volume":"40","author":"Kahlenberg","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"R51-6-20210206","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semarthrit.2008.09.002","article-title":"Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients.","volume":"39","author":"Espinosa","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"R52-6-20210206","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity.","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"R53-6-20210206","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jns.2013.08.034","article-title":"Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica.","volume":"335","author":"Woodhall","year":"2013","journal-title":"J Neurol Sci"},{"key":"R54-6-20210206","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"R55-6-20210206","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"R56-6-20210206","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1212\/WNL.0b013e318293e346","article-title":"Teaching neuroimages: pancake-like gadolinium enhancement suggests compressive myelopathy due to spondylosis.","volume":"80","author":"Flanagan","year":"2013","journal-title":"Neurology"},{"key":"R57-6-20210206","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MAJ.0b013e3182808781","article-title":"Spinal cord neurosarcoidosis.","volume":"347","author":"Sohn","year":"2014","journal-title":"Am J Med Sci"},{"key":"R58-6-20210206","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.mayocp.2013.07.019","article-title":"18F-Fluorodeoxyglucose-positron emission tomography in patients with active myelopathy.","volume":"88","author":"Flanagan","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"R59-6-20210206","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.0b013e3182684672","article-title":"MRI and PET imaging discordance in neurosarcoidosis.","volume":"79","author":"Huang","year":"2012","journal-title":"Neurology"},{"key":"R60-6-20210206","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/jnnp.2007.124263","article-title":"Sarcoidosis of the nervous system.","volume":"7","author":"Joseph","year":"2007","journal-title":"Practical Neurol"},{"key":"R61-6-20210206","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.rmed.2008.08.016","article-title":"Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis.","volume":"103","author":"Sodhi","year":"2009","journal-title":"Respir Med"},{"key":"R63-6-20210206","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1600-0560.2011.01795.x","article-title":"Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab.","volume":"39","author":"Burns","year":"2012","journal-title":"J Cutan Pathol"},{"key":"R64-6-20210206","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1212\/WNL.0b013e3182904d2e","article-title":"Teaching NeuroImages: longitudinally extensive transverse myelitis in neuro-Behcet disease.","volume":"80","author":"Graham","year":"2013","journal-title":"Neurology"},{"key":"R65-6-20210206","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s004150170242","article-title":"Behcets disease: diagnostic and prognostic aspects of neurological involvement.","volume":"248","author":"Siva","year":"2001","journal-title":"J Neurol"},{"key":"R66-6-20210206","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.neurol.2011.09.006","article-title":"Neurological manifestations of Behcets disease: evaluation of 40 patients treated by cyclophosphamide.","volume":"168","author":"Ait Ben Haddou","year":"2012","journal-title":"Rev Neurol (Paris)"},{"key":"R68-6-20210206","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10067-011-1726-1","article-title":"Infliximab for patients with neuro-Behcets disease: case series and literature review.","volume":"30","author":"Borhani Haghighi","year":"2011","journal-title":"Clin Rheumatol"},{"key":"R70-6-20210206","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clineuro.2011.10.024","article-title":"Tocilizumab treatment for neuro-Behcets disease: the first report.","volume":"114","author":"Shapiro","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"key":"R71-6-20210206","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1212\/WNL.0b013e31821f468f","article-title":"Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues.","volume":"76","author":"Flanagan","year":"2011","journal-title":"Neurology"},{"key":"R72-6-20210206","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ana.21324","article-title":"Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G.","volume":"63","author":"Keegan","year":"2008","journal-title":"Ann Neurol"},{"key":"R73-6-20210206","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.4065\/76.11.1120","article-title":"Clinical and radiographic features of dural arteriovenous fistula, a treatable cause of myelopathy.","volume":"76","author":"Atkinson","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"R74-6-20210206","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00415-012-6825-7","article-title":"Acute necrotizing encephalopathy (ANE1): rare autosomal-dominant disorder presenting as acute transverse myelitis.","volume":"260","author":"Wolf","year":"2013","journal-title":"J Neurol"},{"key":"R76-6-20210206","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00234-005-0016-5","article-title":"Imaging features of copper deficiency myelopathy: a study of 25 cases.","volume":"48","author":"Kumar","year":"2006","journal-title":"Neuroradiology"},{"key":"R77-6-20210206","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1212\/01.wnl.0000198770.80743.37","article-title":"Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord.","volume":"66","author":"van der Knaap","year":"2006","journal-title":"Neurology"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WCO.0000000000000093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:53:43Z","timestamp":1620978823000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019052-201406000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0000000000000093","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}